Outcomes of iStent inject combined with cataract surgery in Asian eyes: Australian data from the Fight Glaucoma Blindness international registry.

Huynh, B; Kibret, G; Wechsler, D; Lee, A; Lim, R; Clement, C; Lawlor, M

Outcomes of iStent inject combined with cataract surgery in Asian eyes: Australian data from the Fight Glaucoma Blindness international registry.

Huynh, B Kibret, G Wechsler, D Lee, A Lim, R Clement, C Lawlor, M

Permalink

Publisher:: Springer Nature
Publication Type:: Journal Article
Citation:: Int Ophthalmol, 2024, 44, (1), pp. 200
Issue Date:: 2024-04-25

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Download Published versionAdobe PDF (1.03 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Huynh, B
dc.contributor.author	Kibret, G
dc.contributor.author	Wechsler, D
dc.contributor.author	Lee, A
dc.contributor.author	Lim, R
dc.contributor.author	Clement, C
dc.contributor.author	Lawlor, M
dc.date.accessioned	2025-01-28T05:11:07Z
dc.date.available	2024-03-24
dc.date.available	2025-01-28T05:11:07Z
dc.date.issued	2024-04-25
dc.identifier.citation	Int Ophthalmol, 2024, 44, (1), pp. 200
dc.identifier.issn	0165-5701
dc.identifier.issn	1573-2630
dc.identifier.uri	http://hdl.handle.net/10453/184287
dc.description.abstract	PURPOSE: To analyse real-world outcomes in Asian eyes of iStent inject, a second-generation trabecular micro-bypass stent, combined with phacoemulsification. METHODS: This is a multi-centre, observational study of glaucomatous Asian eyes that have undergone iStent inject implantation combined with cataract surgery. Patient data were extracted from the Fight Glaucoma Blindness! Registry. Outcome measures included those of IOP reduction, glaucoma medication reduction, and adverse events including the need for secondary surgery. RESULTS: 123 eyes of 86 patients with a mean age of 68.4 ± 9.3 years underwent iStent inject implantation with phacoemulsification. At baseline, the mean ± SD preoperative intraocular pressure (IOP) was 16.0 ± 4.4 mmHg, and the mean preoperative number of topical glaucoma medications was 1.9 ± 1.4. At 12 months 30.8% of eyes demonstrated a reduction in IOP greater than 20%, the mean IOP reduction was 12.5% with an additional reduction of 0.7 glaucoma medications. 40% of eyes were using no medications at 12 months compared to 16.3% preoperatively. 8.2% of eyes required a subsequent procedure within the 12-month follow-up window. CONCLUSION: iStent inject implantation combined with phacoemulsification in Asian eyes showed a reduction of IOP and glaucoma medication use in a real-world clinical setting. The safety profile of the device is good with minimal adverse outcomes, however, a subset of patients required secondary procedures within the 12 month follow up.
dc.format	Electronic
dc.language	eng
dc.publisher	Springer Nature
dc.relation.ispartof	Int Ophthalmol
dc.relation.isbasedon	10.1007/s10792-024-03104-x
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	1113 Opthalmology and Optometry
dc.subject.classification	Ophthalmology & Optometry
dc.subject.classification	3212 Ophthalmology and optometry
dc.subject.mesh	Humans
dc.subject.mesh	Male
dc.subject.mesh	Female
dc.subject.mesh	Aged
dc.subject.mesh	Registries
dc.subject.mesh	Intraocular Pressure
dc.subject.mesh	Middle Aged
dc.subject.mesh	Glaucoma Drainage Implants
dc.subject.mesh	Australia
dc.subject.mesh	Visual Acuity
dc.subject.mesh	Treatment Outcome
dc.subject.mesh	Glaucoma
dc.subject.mesh	Phacoemulsification
dc.subject.mesh	Follow-Up Studies
dc.subject.mesh	Aged, 80 and over
dc.subject.mesh	Asian People
dc.subject.mesh	Cataract
dc.subject.mesh	Retrospective Studies
dc.subject.mesh	Humans
dc.subject.mesh	Cataract
dc.subject.mesh	Glaucoma
dc.subject.mesh	Treatment Outcome
dc.subject.mesh	Phacoemulsification
dc.subject.mesh	Registries
dc.subject.mesh	Retrospective Studies
dc.subject.mesh	Follow-Up Studies
dc.subject.mesh	Glaucoma Drainage Implants
dc.subject.mesh	Intraocular Pressure
dc.subject.mesh	Visual Acuity
dc.subject.mesh	Aged
dc.subject.mesh	Aged, 80 and over
dc.subject.mesh	Middle Aged
dc.subject.mesh	Australia
dc.subject.mesh	Female
dc.subject.mesh	Male
dc.subject.mesh	Asian People
dc.subject.mesh	Humans
dc.subject.mesh	Male
dc.subject.mesh	Female
dc.subject.mesh	Aged
dc.subject.mesh	Registries
dc.subject.mesh	Intraocular Pressure
dc.subject.mesh	Middle Aged
dc.subject.mesh	Glaucoma Drainage Implants
dc.subject.mesh	Australia
dc.subject.mesh	Visual Acuity
dc.subject.mesh	Treatment Outcome
dc.subject.mesh	Glaucoma
dc.subject.mesh	Phacoemulsification
dc.subject.mesh	Follow-Up Studies
dc.subject.mesh	Aged, 80 and over
dc.subject.mesh	Asian People
dc.subject.mesh	Cataract
dc.subject.mesh	Retrospective Studies
dc.title	Outcomes of iStent inject combined with cataract surgery in Asian eyes: Australian data from the Fight Glaucoma Blindness international registry.
dc.type	Journal Article
utslib.citation.volume	44
utslib.location.activity	Netherlands
utslib.for	1113 Opthalmology and Optometry
utslib.copyright.status	open_access	*
dc.rights.license	This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0). To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.date.updated	2025-01-28T05:11:04Z
pubs.issue	1
pubs.publication-status	Published online
pubs.volume	44
utslib.citation.issue	1

Abstract:

PURPOSE: To analyse real-world outcomes in Asian eyes of iStent inject, a second-generation trabecular micro-bypass stent, combined with phacoemulsification. METHODS: This is a multi-centre, observational study of glaucomatous Asian eyes that have undergone iStent inject implantation combined with cataract surgery. Patient data were extracted from the Fight Glaucoma Blindness! Registry. Outcome measures included those of IOP reduction, glaucoma medication reduction, and adverse events including the need for secondary surgery. RESULTS: 123 eyes of 86 patients with a mean age of 68.4 ± 9.3 years underwent iStent inject implantation with phacoemulsification. At baseline, the mean ± SD preoperative intraocular pressure (IOP) was 16.0 ± 4.4 mmHg, and the mean preoperative number of topical glaucoma medications was 1.9 ± 1.4. At 12 months 30.8% of eyes demonstrated a reduction in IOP greater than 20%, the mean IOP reduction was 12.5% with an additional reduction of 0.7 glaucoma medications. 40% of eyes were using no medications at 12 months compared to 16.3% preoperatively. 8.2% of eyes required a subsequent procedure within the 12-month follow-up window. CONCLUSION: iStent inject implantation combined with phacoemulsification in Asian eyes showed a reduction of IOP and glaucoma medication use in a real-world clinical setting. The safety profile of the device is good with minimal adverse outcomes, however, a subset of patients required secondary procedures within the 12 month follow up.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/184287